Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics
company, today announced that favorable data regarding its lead
product VitaGraft™ Kidney was published in the New England
Journal of Medicine. Oncocyte’s Drs. Ekke Schuetz and Julia Beck,
inventors of the technology, are among the authors of the study.
VitaGraft Kidney was used to monitor graft injury in a phase 2
double-blind, placebo-controlled study (NCT05021484) of the
investigational drug felzartamab, a fully human CD38 monoclonal
antibody, for antibody-mediated rejection (AMR), a leading cause of
kidney allograft failure.
VitaGraft Kidney measures the amount of DNA in
transplant patients’ blood that comes from the donor organ, a key
biomarker for assessing graft health. This process is commonly
referred to as donor-derived cell-free DNA (dd-cfDNA) testing and
is widely used in clinical practice today. In this study,
Oncocyte’s proprietary diagnostic test using droplet-digital PCR
was able to identify responders and non-responders to felzartamab,
showing, “a decrease in dd-cfDNA fractions at week 12 (0.33%
[0.25−0.40] versus 0.95% [0.37−1.63]; mean difference: −0.75%; 95%
CI: −1.41, −0.09) and week 24 (0.31% [0.21−0.49] versus 0.82%
[0.34−2.90]).”
The study points to new clinical utilities for
VitaGraft Kidney beyond the Company’s currently approved and
reimbursed indication of for cause testing. Both therapeutic
efficacy and recurrence monitoring are potential new use cases for
dd-cfDNA testing. Both utilities would be expected to require
multiple tests during the active management phase, when a drug is
being given, and long-term to help doctors watch for AMR
recurrence.
“The results of the phase 2 trial suggested that
monitoring of dd-cfDNA could be useful to accurately detect
responsiveness to felzartamab therapy, also uncovering disease
recurrence after stopping treatment,” said Dr. Georg Böemig,
Medical University of Vienna, senior author of the publication.
“Therefore, the assay could have high potential as a tool to
individually guide dosing intervals and duration of anti-rejection
therapy.”
Up to 20.2% of kidney transplant patients will
develop AMR within 10 years of transplant and up to 70% of those
patients will progress to graft failure.1 Currently, there are no
FDA approved drugs that have indications for the management of AMR.
Results of the phase 2 trial suggest that the combination of
felzartamab drug therapy and VitaGraft Kidney testing may have
significant potential to address this key unmet need in transplant
management by enabling detection, management, and monitoring of
AMR.
“We congratulate the research teams on this
groundbreaking study and its potential to lead to a treatment
option for kidney transplant patients suffering from AMR around the
world,” said Josh Riggs, Oncocyte CEO. “We are grateful for the
support from our research partners and their inclusion of our test
in this study. It is exciting to see a new opportunity for
Oncocyte’s technology to serve the clinical market and patients in
need. This study, combined with earlier results showing that our
test can detect AMR up to 10 months earlier than protocol, points
to new opportunities to improve care and outcomes for these
high-risk patients. In the future, we expect that VitaGraft will be
there to support physicians looking to detect AMR as early as
possible and then effectively manage this disease.”
“Our recent partnership with Bio-Rad, gives us
the scale we need to support the global transplant research
community with easy-to-use dd-cfDNA monitoring tools,” continued
Mr. Riggs. “Use cases like this will help drive adoption of our
combined technology around the world.”
The results of this publication will be
discussed as a Late Breaking Abstract at the 2024 American
Transplant Congress on June 3rd 2024 at 9:15 ET by Dr. Katharina
Mayer from the Medical University of Vienna. Oncocyte will be
exhibiting at the conference at Booth #430.
Oncocyte will be hosting a conference call to
discuss the results of the clinical trial with study authors, Dr.
Klemens Budde, Head of Transplantation at Charite, and Dr. Ekke
Schuetz, Chief Science Officer at Oncocyte. Dr. Schuetz developed
the dd-cfDNA technology as CEO and CSO of Oncocyte subsidiary
Chronix Biomedical alongside Dr. Julia Beck. The clinical
presentation will be followed by an operational update and Q&A
focused on the commercial launches of VitaGraft Kidney and
GraftAssure by Josh Riggs. Investors may submit questions for the
Q&A by emailing them to the contact information listed below.
The date and time of the call will be announced in due course.
1 Mujtahedi, S.S., Yigitbilek, F., Ozdogan, E.
et al. Antibody-Mediated Rejection: the Role of Plasma Cells and
Memory B Cells. Curr Transpl Rep 8, 272–280 (2021).
https://doi.org/10.1007/s40472-021-00342-1
About Oncocyte
Oncocyte is a precision diagnostics company. The
Company’s tests are designed to help provide clarity and confidence
to physicians and their patients. VitaGraft™ is a clinical
blood-based solid organ transplantation monitoring test.
GraftAssure™ is a research use only (RUO) blood-based solid organ
transplantation monitoring test. DetermaIO™ is a gene expression
test that assesses the tumor microenvironment to predict response
to immunotherapies. DetermaCNI™ is a blood-based monitoring tool
for monitoring therapeutic efficacy in cancer patients. For more
information about Oncocyte, please
visit https://oncocyte.com/. For more information about our
products, please visit the following web pages:
VitaGraft Kidney™
- https://oncocyte.com/vitagraft-kidney/VitaGraft Liver™
- https://oncocyte.com/vitagraft-liver/GraftAssure™
- https://oncocyte.com/graftassure/DetermaIO™
- https://oncocyte.com/determa-io/DetermaCNI™
- https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and
DetermaCNI™ are trademarks of Oncocyte Corporation.
About Antibody-Mediated Rejection (AMR) in Kidney
Transplant Recipients
Antibody-mediated rejection (AMR) is a major cause of kidney
transplant failure, with late AMR affecting approximately 23,000
patients total in the U.S. There is no effective treatment for AMR
and patient options are highly limited. Donor-specific antibody
(DSA) production by plasma cells, and tissue infiltration of
Natural Killer (NK) cells presumed to be involved in DSA-dependent
microvascular inflammation, are both linked to AMR. Observations
that both plasma cells and NK cells express high levels of CD38
have motivated the approach of targeting CD38 to deplete these cell
populations to address AMR.
About Felzartamab
Felzartamab is an investigational therapeutic human monoclonal
antibody directed against CD38, a protein expressed on mature
plasma cells. Felzartamab has been shown in clinical studies to
selectively deplete CD38+ plasma cells, which may allow
applications that ultimately improve clinical outcomes in a broad
range of diseases driven by pathogenic antibodies. Felzartamab is
an investigational therapeutic candidate that has not yet been
approved by any regulatory authority.
Forward-Looking Statements
Any statements that are not historical fact
(including, but not limited to statements that contain words such
as “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” “may,” and similar expressions) are forward-looking
statements. These statements include those pertaining to, among
other things, the future of VitaGraft Kidney, the anticipation that
Oncocyte and Bio-Rad's combined technology will be adopted around
the world, and other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management.
Forward-looking statements involve risks and uncertainties,
including, without limitation, the potential impact of COVID-19 on
Oncocyte or its subsidiaries’ financial and operational results,
risks inherent in the development and/or commercialization of
diagnostic tests or products, uncertainty in the results of
clinical trials or regulatory approvals, the capacity of Oncocyte’s
third-party supplied blood sample analytic system to provide
consistent and precise analytic results on a commercial scale,
potential interruptions to supply chains, the need and ability to
obtain future capital, maintenance of intellectual property rights
in all applicable jurisdictions, obligations to third parties with
respect to licensed or acquired technology and products, the need
to obtain third party reimbursement for patients’ use of any
diagnostic tests Oncocyte or its subsidiaries commercialize in
applicable jurisdictions, and risks inherent in strategic
transactions such as the potential failure to realize anticipated
benefits, legal, regulatory or political changes in the applicable
jurisdictions, accounting and quality controls, potential greater
than estimated allocations of resources to develop and
commercialize technologies, or potential failure to maintain any
laboratory accreditation or certification. Actual results may
differ materially from the results anticipated in these
forward-looking statements and accordingly such statements should
be evaluated together with the many uncertainties that affect the
business of Oncocyte, particularly those mentioned in the “Risk
Factors” and other cautionary statements found in Oncocyte’s
Securities and Exchange Commission (SEC) filings, which are
available from the SEC’s website. You are cautioned not to place
undue reliance on forward-looking statements, which speak only as
of the date on which they were made. Oncocyte undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made,
except as required by law.
CONTACT:
Jeff RamsonPCG Advisory(646) 863-6893jramson@pcgadvisory.com
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024